Clovis Oncology, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-09: Form 8-K; Period of report 2013-12-03; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2013-11-19: Form 8-K; Period of report 2013-11-19; Description 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; Details 2.01.
- 2013-10-31: Form 8-K; Period of report 2013-10-31; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-08-01: Form 8-K; Period of report 2013-08-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-09 | 8-K | 2013-12-03 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On December 3, 2013, Clovis Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the selling stockholders named therein (the “Selling Stockholders”) and J.P. Morgan Securities LLC as underwriter (the “Underwriter”), relating to the sale of 2,000,000 shares of the Company’s common stock (the “Offering”), par value $0.001 per share, by the Selling Stockholders in an underwritten public offering. 8.01 The Company provided a supplemental risk factor in the prospectus supplement used in connection with the Offering. | d638236d8k.htm |
| 2013-11-19 | 8-K | 2013-11-19 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities | 2.01 On November 19, 2013, Clovis Oncology, Inc. (the “Company” or “Clovis”) acquired (the “Acquisition”) all of the issued and outstanding capital stock of EOS pursuant to the terms set forth in that certain Stock Purchase Agreement, dated as of November 19, 2013 (the “Stock Purchase Agreement”), by and among the Company, EOS, its shareholders (the “Sellers”) and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ representative. 3.02 The description of the Stock Purchase Agreement set forth in Item 1.01 and Item 2.01 above is incorporated by reference into this Item 3.02. | d627388d8k.htm |
| 2013-10-31 | 8-K | 2013-10-31 | 2.02 Results of Operations and Financial Condition | 2.02 On October 31, 2013, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2013. | a50741595.htm |
| 2013-08-01 | 8-K | 2013-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2013, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2013. | a50682781.htm |
| 2013-06-17 | 8-K | 2013-06-11 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On June 11, 2013, Clovis Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale of 3,333,334 shares of common stock, par value $0.001 per share, of the Company. 8.01 On June 10, 2013, the Company issued a press release announcing the commencement of the offering. | d553948d8k.htm |
| 2013-06-14 | 8-K | 2013-06-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 13, 2013, the Board of Directors (the “Board”) of Clovis Oncology, Inc. (the “Company”) increased the number of members of the Board from eight (8) to nine (9). 5.07 The Annual Meeting of Shareholders (the “Annual Meeting”) of the Company was held on June 13, 2013. | d554084d8k.htm |
| 2013-06-03 | 8-K | 2013-06-03 | 8.01 Other Events | 8.01 On June 3, 2013, Clovis Oncology, Inc. issued a press release announcing initial findings from an ongoing Phase I/II monotherapy study of rucaparib, the company’s oral, potent, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed for the treatment of ovarian cancer. | a50644521.htm |
| 2013-06-03 | 8-K | 2013-06-03 | 8.01 Other Events | 8.01 On June 3, 2013, Clovis Oncology, Inc. issued a press release announcing initial clinical data from the Phase I portion of its ongoing Phase I/II clinical study of CO-1686, the company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. | a50644523.htm |
| 2013-05-07 | 8-K | 2013-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2013, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2013. | a50626423.htm |
| 2013-02-28 | 8-K | 2013-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2013, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2012. | a50580813.htm |
| 2013-02-19 | 8-K | 2013-02-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 14, 2013, Dr. John C. Reed informed Clovis Oncology, Inc. (the “Company”) that he would resign from the Board of Directors of the Company effective immediately. | d489302d8k.htm |
| 2013-01-09 | 8-K | 2013-01-07 | 2.02 Results of Operations and Financial Condition | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2012, on January 7, 2013, Clovis Oncology, Inc. (the “Company”) issued a press release announcing that the Company had approximately $144.0 million in cash as of December 31, 2012 and expects a cash burn of $53.0 to $57.0 million for the year ending December 31, 2013, which would result in the Company having approximately $90 million in cash as of December 31, 2013. | d463471d8k.htm |